Google has claimed an advance in quantum computing that is a milestone towards its practical applications in areas like drug discovery.
Enhancing neuropsychological assessment clinical pathways in Parkinson’s disease through the use of technology
BackgroundRoutine administration of neuropsychological assessments to evaluate cognitive decline in Parkinson’s disease (PD) may not be feasible in current clinical services. This is due to lengthy administration time, lack of specialised neuropsychologists and other limitations in resources. While technology integration could improve efficiency, understanding the existing assessment journey is crucial for successful implementation in clinical […]
Havas Lynx presses pharma to pivot from ‘selling to serving’ to confront health misinformation
In a new white paper, Havas Lynx lays out ways in which pharma marketers can—and should, according to the health comms agency—use their platforms to battle rampant misinformation.
Drug launch prices spiked from 2022 to 2024, new ICER report finds
As newly-launched drugs consistently fetch list prices that exceed $1 million or more, a new ICER report released Thursday finds that even the net prices — once payer discounts are considered — are outpacing inflation and GDP …
Moderna drops mRNA jab for CMV after phase 3 fail
Moderna has decided to halt the development of its mRNA-1647 vaccine for congenital CMV infections, once touted as a future blockbuster.
AstraZeneca-partnered Pinetree nears $47M Series B for protein degraders
Pinetree Therapeutics is on the cusp of closing a $47 million Series B financing, with the goal of invigorating its pipeline following a deal with AstraZeneca last year. Pinetree’s raise is currently in progress and …
Tahoe Therapeutics releases virtual cell AI model
A tiny South San Francisco biotech says it has developed the field’s largest virtual cell model and is giving it away for free. Tahoe Therapeutics drew headlines this spring when it
Roche in talks with US on drug pricing, sets out pipeline and dealmaking ambitions
Roche is in discussions with the US administration on drug pricing, but CEO Thomas Schinecker declined to say whether it might strike a deal similar to those recently cut by its peers Pfizer and …
Alector ditches GSK-partnered dementia drug and cuts staff
Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.
Aligning with regulatory agencies for the use of digital health technologies in drug development: a case study from Parkinson’s disease
Digital Health Technologies (DHTs) have been under investigation for many years as innovative tools for Parkinson’s disease motor symptoms given their inherent high-frequency, sensitive, and objective measurement properties. DHTs used in drug development, can be defined as Drug Development Tools (DDT), though some DHTs may also be categorized as medical devices. The recent rapid increase […]